首页> American Journal of Hematology> De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell lymphoma is associated with prolonged remission.

De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell lymphoma is associated with prolonged remission.

导出原文传递

翻译打印收藏纠错

第一作者： Wong BY

作者： Wong BY ^[1] ; Ma Y ; Fitzwilson R ; Dang NH

作者单位： Department of Hematologic Malignancies, Nevada Cancer Institute, Las Vegas, Nevada 89135, USA. ^[1]

关键词 Ontak denileukin diftitox maintenance therapy Patients Cancer Remission 病人

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

American Journal of Hematology

2008年83卷7期

596-598页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

American Journal of Hematology

2008年83卷7期

596-598页

检索历史清除

De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell lymphoma is associated with prolonged remission.

American Journal of Hematology

相似文献

同项目论文

American Journal of Hematology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell lymphoma is associated with prolonged remission.

American Journal of Hematology

相似文献

同项目论文

American Journal of Hematology

相关期刊

检索历史清除